|
| 38039427 | Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial. | J Clin Oncol | 2024 |
| 38079095 | Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer. | Clin Pharmacokinet | 2024 |
| 36287571 | A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary. | J Pathol | 2023 |
| 37541389 | Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations. | J Thorac Oncol | 2023 |
| 37875771 | A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. | Target Oncol | 2023 |
| 37573702 | Immune-related acute kidney injury in Australian non-small cell lung cancer patients: Real-world results. | Lung Cancer | 2023 |
| 37870973 | First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLC. | N Engl J Med | 2023 |
| 37023987 | Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer. | Int J Radiat Oncol Biol Phys | 2023 |
| 36990577 | Response to Letter to the Editor From Binghao Zhao et al. | J Thorac Oncol | 2023 |
| 37077199 | LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC. | JTO Clin Res Rep | 2023 |
| 37470440 | Comprehensive profiling identifies tumour and immune microenvironmental differences in clinical subsets of cutaneous squamous cell carcinoma. | Br J Dermatol | 2023 |
| 37306090 | Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer. | Future Oncol | 2023 |
| 37270244 | Metastatic Ablation in Epidermal Growth Factor Receptor Mutated Oligometastatic Non-Small Cell Lung Cancer-Upfront or Outback After Systemic Tyrosine Kinase Inhibitors? | Int J Radiat Oncol Biol Phys | 2023 |
| 37295609 | Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC. | J Thorac Oncol | 2023 |
| 37163707 | Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress. | Am Soc Clin Oncol Educ Book | 2023 |
| 36656302 | A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data. | Future Oncol | 2023 |
| 36872130 | Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2023 |
| 36535300 | Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. | Lancet Respir Med | 2023 |
| 36638198 | A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study. | Clin Cancer Res | 2023 |
| 36764316 | Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trial. | Lancet | 2023 |
| 36669645 | Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2023 |
| 36895924 | Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer-a narrative review. | Transl Lung Cancer Res | 2023 |
| 36307040 | Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. | J Thorac Oncol | 2023 |
| 36122315 | Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. | J Clin Oncol | 2023 |
| 35023475 | Pitfalls and progress in adrenocortical carcinoma diagnosis: the utility of a multidisciplinary approach, immunohistochemistry and genomics. | Endocrinol Diabetes Metab Case Rep | 2022 |
| 35740537 | A Laboratory-Friendly CTC Identification: Comparable Double-Immunocytochemistry with Triple-Immunofluorescence. | Cancers (Basel) | 2022 |
| 35605188 | Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i>-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. | J Clin Oncol | 2022 |
| 35660971 | Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. | Lung Cancer | 2022 |
| 35525376 | Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103<sup>+</sup> immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials. | Ann Oncol | 2022 |
| 36410210 | Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. | Lung Cancer | 2022 |
| 36108261 | Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies. | JCO Precis Oncol | 2022 |
| 35970920 | Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. | Nat Med | 2022 |
| 36030187 | A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases. | Clin Lung Cancer | 2022 |
| 36324736 | Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high <i>ACE2</i>-expressing normal lung. | Ther Adv Med Oncol | 2022 |
| 36151006 | Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations. | Clin Lung Cancer | 2022 |
| 34890832 | Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. | Lung Cancer | 2022 |
| 35183043 | Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations. | ESMO Open | 2022 |
| 35307972 | A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. | Cancer Med | 2022 |
| 35085007 | Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. | JCO Precis Oncol | 2022 |
| 35026476 | Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease. | J Thorac Oncol | 2022 |
| 34994987 | Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer. | Cochrane Database Syst Rev | 2022 |
| 33150799 | Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancer. | Future Oncol | 2021 |
| 33911192 | Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. | NPJ Precis Oncol | 2021 |
| 33788170 | Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy. | J Cancer Surviv | 2021 |
| 33618863 | Alectinib induces marked red cell spheroacanthocytosis in a near-ubiquitous fashion and is associated with reduced eosin-5-maleimide binding. | Pathology | 2021 |
| 33509972 | A Phase 1 and Biodistribution Study of ABT-806i, an <sup>111</sup>In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806. | J Nucl Med | 2021 |
| 33758378 | Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. | Nat Rev Clin Oncol | 2021 |
| 33639216 | Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. | Ann Oncol | 2021 |
| 33723371 | COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. | Nat Rev Clin Oncol | 2021 |
| 34994633 | Novel RET Fusion <i>RET-SEPTIN9</i> Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma. | JCO Precis Oncol | 2021 |